Rapatinib is a novel tyrosine kinase inhibitor that targets the switch pocket regions of KIT and PDGFRA kinases through a unique dual inhibition mechanism, effectively overcoming resistance issues in GIST patients. Its mechanism of action mainly involves specific inhibition of kinase activity conformation, providing treatment options for late stage drug-resistant patients.

Dual inhibition mechanism of ripitinib

(1) Switching pocket binding: Rapatinib stabilizes the inactive conformation of KIT and PDGFRA kinases by binding to their switching pocket regions, blocking their activation signal transduction. This binding method is different from traditional ATP competitive inhibitors and can effectively avoid the effects of common resistance mutations.

(2) Dual inhibitory effect: The drug simultaneously acts on the activation loop and phosphate binding loop of the kinase, forming a dual conformational lock. This unique mechanism maintains its activity against multiple secondary drug-resistant mutations, including KIT exon 13/14/17/18 mutations.

Molecular level action characteristics

(3) Conformational selectivity: Rapatinib exhibits high selectivity towards the inactive DFG out conformation of kinases, with binding affinity 10-100 times higher than traditional inhibitors. This characteristic enables it to effectively suppress drug-resistant mutations caused by conformational changes.

(4) Signal pathway blockade: By inhibiting KIT/PDGFRA kinase activity, downstream pro survival signaling pathways such as STAT3, PI3K/AKT, and MAPK are significantly inhibited, leading to tumor cell cycle arrest and apoptosis.

Clinical advantages

(5) Broad spectrum anti mutation: Compared to traditional TKIs, ripitinib is effective against both primary and secondary drug-resistant mutations, particularly exhibiting significant inhibitory activity against KIT exon 17 mutations (such as D816V) and PDGFRAD842V mutations.

(6) Synergistic inhibitory effect: Its dual mechanism can produce a synergistic effect with existing TKIs, providing new treatment opportunities for patients who have failed sequential therapy. Clinical studies have shown that even patients with triple resistance to imatinib, sunitinib, and regorafenib can still achieve a disease control rate of over 40%.